Open Access<p>Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials</p>
Author(s) -
Michael Singer,
Mimi Liu,
Patricio G. Schlottmann,
Arshad M. Khanani,
Miranda Hemphill,
Lauren Hill,
Lisa Tuomi,
Zdenka Hašková
Publication year - 2020
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s247061
Subject(s) - medicine , ranibizumab , diabetic retinopathy , ophthalmology , diabetic macular edema , post hoc analysis , diabetes mellitus , macular edema , visual acuity , bevacizumab , chemotherapy , endocrinology
To investigate the predictors of early diabetic retinopathy (DR) improvement in the RIDE/RISE (NCT00473382/NCT00473330) clinical trials.